Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment

Since 2013, trastuzumab emtansine (T-DM1) has been widely used in Japan to treat patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who were previously administered trastuzumab and a taxane. However, there is no information about the treatment outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanuki, Rurina, Shimomura, Akihiko, Yazaki, Shu, Noda-Narita, Shoko, Sumiyoshi-Okuma, Hitomi, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Yonemori, Kan, Tamura, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505390/
https://www.ncbi.nlm.nih.gov/pubmed/32957402
http://dx.doi.org/10.1097/MD.0000000000022331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505390/
https://www.ncbi.nlm.nih.gov/pubmed/32957402
http://dx.doi.org/10.1097/MD.0000000000022331

Ejemplares similares